BIOHIGH SIGNALFINANCIAL10-K

Bio-Rad experienced a dramatic financial turnaround with net income swinging from -$1.8B loss to $759.9M profit, despite operating income plummeting 82.5%.

The massive swing from significant net loss to substantial profit, combined with collapsing operating income, suggests major non-operating events occurred during the period - likely asset sales, investment gains, or extraordinary items that masked underlying operational deterioration. This disconnect between operating performance and net income raises questions about the sustainability of earnings and the company's core business health.

Comparing 2026-02-13 vs 2025-02-14View on EDGAR →
FINANCIAL ANALYSIS

Bio-Rad shows a mixed financial picture with strong balance sheet growth (assets up 12.9%, equity up 13.5%) and improved cash generation (operating cash flow up 16.9%), but severely weakened core operations as evidenced by the 82.5% decline in operating income. The company appears financially stable with increased share buybacks ($295.5M vs $203.6M) and manageable liability growth, though the dramatic divergence between operating losses and net profit gains suggests significant one-time events drove the headline earnings improvement. Overall, the financial health appears solid but operational performance has materially deteriorated.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+141.2%
-$1.8B→$759.9M

Net income grew 141.2% — bottom-line growth signals improving overall business health.

Operating Income
P&L
-82.5%
$269.0M→$47.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Share Buybacks
Cash Flow
+45.1%
$203.6M→$295.5M

Share repurchases increased 45.1% — management returning capital, signals confidence in intrinsic value.

Operating Cash Flow
Cash Flow
+16.9%
$455.2M→$532.2M

Operating cash flow grew 16.9% — strong conversion of earnings to cash, healthy business fundamentals.

Stockholders Equity
Balance Sheet
+13.5%
$6.6B→$7.5B

Equity base grew 13.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+12.9%
$9.4B→$10.6B

Asset base grew 12.9% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
+11.7%
$2.8B→$3.1B

Liabilities increased 11.7% — monitor debt-to-equity ratio and interest coverage.

Current Liabilities
Balance Sheet
+10.5%
$467.8M→$517.0M

Current liabilities rose 10.5% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-13
PRIOR — 2025-02-14
ADDED
As of February 9, 2026, there were 21,924,284 shares of Class A Common Stock and 5,066,110 shares of Class B Common Stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 7A.
(referred to in this report as Bio-Rad, we, us, the Company, and our ) is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables.
We have direct operations in over 36 countries outside the United States through subsidiaries focused on sales, customer service, and product distribution.
In certain locations outside and within these countries, our sales efforts are supplemented by distributors and agents.
+7 more — sign up free →
REMOVED
As of February 11, 2025, there were 22,940,805 shares of Class A Common Stock and 5,070,337 shares of Class B Common Stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 7A.
(referred to in this report as Bio-Rad, we, us, the Company and our ) is a multinational developer, manufacturer, and worldwide distributor of our own life science research and clinical diagnostics products.
Bio-Rad develops, manufactures, and supplies life science research, healthcare, analytical chemistry and other markets with a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
We have direct distribution channels in over 36 countries outside the United States through subsidiaries whose focus is sales, customer service and product distribution.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →